68Ga-NI-FAPI PET/CT: First-in-human Study

Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Nov 12, 2024

Keywords

ClinConnect Summary

This clinical trial, called the 68Ga-NI-FAPI PET/CT study, is exploring a new imaging tool to help doctors see how different types of cancer behave in the body. The test uses a special substance, known as a radiotracer, that can highlight cancer cells during a PET scan, which is a type of imaging that shows how organs and tissues are functioning. The researchers want to ensure that this new tool is safe and effective for patients with various solid tumors, which are abnormal growths that can occur in different parts of the body.

To participate in this study, potential participants must have a confirmed diagnosis of certain types of solid tumors and be between the ages of 65 and 74. They should also be able to provide informed consent by understanding the trial's purpose and agreeing to take part. Unfortunately, pregnant or breastfeeding women and those with serious liver or kidney problems cannot join. If someone is eligible and agrees to participate, they can expect to receive this new imaging test, which aims to improve how doctors diagnose and treat cancer. The study is currently looking for volunteers, and the knowledge gained could help improve cancer care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Various solid tumors with available histopathological findings
• • Signed informed consent
• Exclusion Criteria:
• • pregnant or lactational women
• • who suffered from severe hepatic and renal insufficiency